Mitch Raponi

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung
    Mitch Raponi
    Molecular Diagnostics, Veridex LLC a Johnson and Johnson Company, 3210 Merryfriend Row, San Diego, CA 92121, USA
    Cancer Res 66:7466-72. 2006
  2. pmc Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia
    Mitch Raponi
    Veridex, LLC, Johnson and Johnson Company, San Diego, CA 9212, USA
    BMC Cancer 4:56. 2004
  3. ncbi Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia
    Mitch Raponi
    Veridex, L L C a Johnson and Johnson Company, San Diego, California 92121, USA
    Clin Cancer Res 13:2254-60. 2007
  4. ncbi A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
    Mitch Raponi
    Veridex, 3210 Merryfield Row, La Jolla, CA 92121, USA
    Blood 111:2589-96. 2008
  5. ncbi RNA-mediated gene silencing in non-pathogenic and pathogenic fungi
    Marianne D De Backer
    Johnson and Johnson Pharmaceutical Research and Development, Department GI Emerging Diseases, Turnhoutseweg 30, B 2340, Beerse, Belgium
    Curr Opin Microbiol 5:323-9. 2002
  6. doi MicroRNA classifiers for predicting prognosis of squamous cell lung cancer
    Mitch Raponi
    Centocor Research and Development, Radnor, Pennsylvania 19087, USA
    Cancer Res 69:5776-83. 2009
  7. doi KRAS mutations predict response to EGFR inhibitors
    Mitch Raponi
    Centocor R and D, 145 King of Prussia Road, Radnor, PA 19086, USA
    Curr Opin Pharmacol 8:413-8. 2008
  8. ncbi Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients
    Janet L MacPherson
    Johnson and Johnson Research Pty Limited, Locked Bag 4555, Strawberry Hills, Sydney, NSW Australia 2012
    J Gene Med 7:552-64. 2005
  9. doi Development of genomic markers that predict response to molecularly targeted antileukemic therapy
    Mitch Raponi
    Veridex, LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA 1 858 320 3319 1 858 784 3182
    Expert Opin Med Diagn 2:361-72. 2008
  10. pmc Dominant genetic screen for cofactors that enhance antisense RNA-mediated gene silencing in fission yeast
    Mitch Raponi
    Department of Biochemistry and Molecular Genetics, University of New South Wales, Sydney, NSW 2052, Australia
    Nucleic Acids Res 30:2546-54. 2002

Collaborators

Detail Information

Publications12

  1. ncbi Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung
    Mitch Raponi
    Molecular Diagnostics, Veridex LLC a Johnson and Johnson Company, 3210 Merryfriend Row, San Diego, CA 92121, USA
    Cancer Res 66:7466-72. 2006
    ..0002; HR, 3.54; 95% CI, 1.74-7.19). This prognostic signature could be used to identify patients with early-stage high-risk NSCLC who might benefit from adjuvant therapy following surgery...
  2. pmc Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia
    Mitch Raponi
    Veridex, LLC, Johnson and Johnson Company, San Diego, CA 9212, USA
    BMC Cancer 4:56. 2004
    ..This study was conducted to identify genetic markers and pathways that are regulated by tipifarnib in acute myeloid leukemia (AML)...
  3. ncbi Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia
    Mitch Raponi
    Veridex, L L C a Johnson and Johnson Company, San Diego, California 92121, USA
    Clin Cancer Res 13:2254-60. 2007
    ..Microarray technology was used to identify gene expression markers that predict response to the orally available farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in acute myelogenous leukemia (AML)...
  4. ncbi A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
    Mitch Raponi
    Veridex, 3210 Merryfield Row, La Jolla, CA 92121, USA
    Blood 111:2589-96. 2008
    ..Therefore, these data indicate that a 2-gene expression assay may have utility in categorizing a population of patients with AML who are more likely to respond to tipifarnib...
  5. ncbi RNA-mediated gene silencing in non-pathogenic and pathogenic fungi
    Marianne D De Backer
    Johnson and Johnson Pharmaceutical Research and Development, Department GI Emerging Diseases, Turnhoutseweg 30, B 2340, Beerse, Belgium
    Curr Opin Microbiol 5:323-9. 2002
    ..We focus on the recent advances in RNA-mediated gene silencing technologies and their potential for functional genomics studies in fungi...
  6. doi MicroRNA classifiers for predicting prognosis of squamous cell lung cancer
    Mitch Raponi
    Centocor Research and Development, Radnor, Pennsylvania 19087, USA
    Cancer Res 69:5776-83. 2009
    ..Our data indicate that miRNAs may have greater clinical utility in predicting the prognosis of patients with squamous cell lung carcinomas than mRNA-based signatures...
  7. doi KRAS mutations predict response to EGFR inhibitors
    Mitch Raponi
    Centocor R and D, 145 King of Prussia Road, Radnor, PA 19086, USA
    Curr Opin Pharmacol 8:413-8. 2008
    ..Recent clinical data have provided substantial evidence that KRAS mutational status should be utilized as a diagnostic marker for predicting that response to anti-EGFR therapies in colorectal and non-small cell lung cancer...
  8. ncbi Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients
    Janet L MacPherson
    Johnson and Johnson Research Pty Limited, Locked Bag 4555, Strawberry Hills, Sydney, NSW Australia 2012
    J Gene Med 7:552-64. 2005
    ..We report here the results of a phase I gene transfer clinical trial using Rz2...
  9. doi Development of genomic markers that predict response to molecularly targeted antileukemic therapy
    Mitch Raponi
    Veridex, LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA 1 858 320 3319 1 858 784 3182
    Expert Opin Med Diagn 2:361-72. 2008
    ..Conclusion: The integration of validated genomic-based assays with common morphological tests may allow for improved prediction of antileukemic drug response...
  10. pmc Dominant genetic screen for cofactors that enhance antisense RNA-mediated gene silencing in fission yeast
    Mitch Raponi
    Department of Biochemistry and Molecular Genetics, University of New South Wales, Sydney, NSW 2052, Australia
    Nucleic Acids Res 30:2546-54. 2002
    ..These findings demonstrate the utility of this strategy in identifying host-encoded factors that can modulate gene silencing when co-expressed with antisense RNA and possibly other forms of gene-silencing activators...
  11. ncbi Control of specific gene expression in mammalian cells by co-expression of long complementary RNAs
    Nham Tran
    Johnson and Johnson Research Pty Ltd, 1 Central Ave, Australian Technology Park, Eveleigh, NSW 1430, Australia
    FEBS Lett 573:127-34. 2004
    ..This complementary RNA co-expression approach permits the use of long complementary RNAs for regulating specific gene expression in mammalian cells...
  12. pmc Double-stranded RNA-mediated gene silencing in fission yeast
    Mitch Raponi
    Department of Biochemistry and Molecular Genetics, University of New South Wales, Sydney, NSW 2052, Australia
    Nucleic Acids Res 31:4481-9. 2003
    ..Taken together, these data indicate that RNA-mediated gene silencing can occur through a RNAi-like mechanism in fission yeast...